Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection.

摘要: Aims In order to avoid the potential for elevated serum lipid levels as a consequence of long term sedation with propofol, formulation propofol 6% in Lipofundin® MCT/LCT 10% (Propofol SAZN) has been developed. The pharmacokinetics, induction anaesthesia and safety characteristics this new were investigated after bolus injection compared commercially available product (propofol 1% Intralipid® 10%, Diprivan®-10) SAZN). Methods In randomised double-blind study, 24 unpremedicated female patients received an dose 2.5 mg kg−1 over 60 s which was followed by standardized balanced anaesthesia. randomized receive Propofol SAZN, SAZN or Diprivan®-10. Results For all formulations pharmacokinetics adequately described tri-exponential equation, concentrations collected early suggested additional initial more rapid phase. average values clearance (CL), volume distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) (t1/2,λ2) observed three groups 32±1.5 ml kg−1 min−1, 2.0±0.18 l kg−1, 95±5.6 min 3.4±0.20 min, respectively (mean±s.e.mean, n=24) no significant differences noted between (P >0.05). phase (t1/2,λ1 ) subjects ranged from 0.1 0.6 min. Anaesthesia induced successfully uneventfully cases, quality adequate patients. time did not vary 51±1.3 s corresponded 2.1±0.06 mg kg−1 n=24). percentage reporting any pain on 17% groups. No postoperative phlebitis other venous sequelae vein used occurred recovery nor 24 h. Conclusions From above results, we conclude that alteration type emulsion higher concentration parenteral does affect currently product. can be administered safely advantage reduction load fat emulsifier may preferable when administration is required.